Sensitive circulating tumor DNA based residual disease detection in epithelial ovarian cancer
We analyzed 264 plasma samples collected between June 2016 and September 2021 from 63 epithelial ovarian cancer patients using tumor-guided plasma cell-free DNA analysis to detect residual disease after treatment.
- 02/04/2024
- 1 sample
- DAC: EGAC50000000177
- Technology: Illumina NovaSeq 6000
Data access policy for study "Sensitive circulating tumor DNA based residual disease detection in epithelial ovarian cancer"
An online data access agreement is to be filled out by the requester: https://forms.gle/VfxH7E961YyFYECw9 The data access committee will evaluate and approve the request for data access.
Studies are experimental investigations of a particular phenomenon, e.g., case-control studies on a particular trait or cancer research projects reporting matching cancer normal genomes from patients.
| Study ID | Study Title | Study Type |
|---|---|---|
| EGAS50000000245 | Cancer Genomics |
This table displays only public information pertaining to the files in the dataset. If you wish to access this dataset, please submit a request. If you already have access to these data files, please consult the download documentation.
| ID | File Type | Size | Located in | |
|---|---|---|---|---|
| EGAF50000091471 | fq.gz | 2.4 GB | ||
| EGAF50000091472 | fq.gz | 2.5 GB | ||
| 2 Files (4.9 GB) | ||||